蛋白酶体抑制剂的合理设计基于内源性抑制剂PI31/Fub1的结构
Benjamin Velez1, Aida Razi1, Robert D Hubbard2
1Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115.
概括
研究人员开发了针对β2活性位点的新型蛋白酶体抑制剂,灵感来自内源性抑制剂PI31/Fub1.1. 这种化合物有效地抑制了多发性骨髓瘤细胞,并与现有药物协同作用,提供了新的治疗策略.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 蛋白酶体抑制剂是重要的抗癌药物,经批准的药物向β5活性位点.
- 内源性抑制剂PI31/Fub1独特地同时针对所有三个蛋白质酶活性位点.
- 现有的疗法面临药物耐药性和严重副作用的挑战.
研究的目的:
- 开发针对β2活性位点的强效和特异性蛋白酶体抑制剂.
- 在多发性骨髓瘤中研究β2抑制剂的治疗潜力.
- 探索涉及β2抑制剂和现有的蛋白酶体抑制剂的组合疗法.
主要方法:
- 利用PI31的抑制机制进行结构导向药物设计.
- 合成和表征了一套新的β2蛋白酶体抑制剂.
- 评估了化合物对多发性骨髓瘤细胞系的疗效.
- 评估了化合物与博特佐米布的协同效应.
主要成果:
- 开发出强效和特定的β2蛋白酶体抑制剂.
- 这种化合物显著抑制了多发性骨髓瘤细胞生长.
- 确认了化合物的细胞透性.
- 在β2抑制剂和博特佐米布 (β5抑制剂) 之间观察到强烈的协同作用.
结论:
- 抑制β2蛋白酶体是一种可行的治疗策略,用于多发性骨髓瘤.
- 开发的β2抑制剂显示出作为独立药物和组合疗法的前景.
- 理性结构引导设计为开发新型蛋白酶体抑制剂提供了有效的方法.
相关概念视频
The Proteasome Structure
763
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
763
The Proteasome
850
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
850
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K


